All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Correspondence published on 30-January 2018 in the British Journal of Haematology by Liam Smyth et al described their phase II study on the use of interferon-alpha (IFN-α) and rituximab (R) maintenance after autologous stem cell transplant (ASCT) in relapsed/refractory (R/R) follicular lymphoma (FL). Following evidence from a meta-analysis that supported the use of IFN-α in FL, the authors aimed to assess survival outcomes and minimal residual disease (MRD) in patients using this combination of immunotherapy and high dose therapy (HDT).
The treatment protocol involved salvage therapy followed by an in vivo purge with rituximab, and eligible patients then received HDT. Thirty patients (median age = 47 years) were successfully transplanted and treated with R-maintenance with 27 patients receiving IFN-α. Ten of these patients discontinued early whilst 17 patients completed two years of IFN-α with a complete response (CR) rate of 77%.
The median follow-up of this study was 10.3 years, range 1.9–16.2. The median overall survival (OS) was not reached (range = 3.6–16.2 years) and the authors observed a “survival plateau” at 8 years. The median progression-free survival (PFS) was also not reached, range 0.7–15.2 years. The authors found that the remission duration pre-enrolment and secondary malignancy development were factors that significantly affected OS in both univariate and multivariate analysis. MRD was detected using real-time quantitative polymerase chain reaction (PCR) in 22 patients with ten samples showing detectable disease. The authors noted that the difference in PFS was not significantly different in patients who were either MRD positive or negative suggesting that the study regimen was effective at “eradicating residual disease”.
The authors concluded that the positive results from this study demonstrated good survival outcomes with the combination of rituximab, INF-α and ASCT.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox